Around 25% of breast cancer harbors amplification or super expression of human epidermal growth factor receptor 2 (HER2), a core driver for cellular growth, and about 50% of these cases concurrently express hormone receptors (HR). This evidence concerns the gene ERBB2 and breast carcinoma.